- Trials with a EudraCT protocol (368)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
368 result(s) found for: Carcinoma, Hepatocellular.
Displaying page 8 of 19.
| EudraCT Number: 2019-002491-14 | Sponsor Protocol Number: WO41535 | Start Date*: 2019-12-17 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOM... | |||||||||||||
| Medical condition: High-risk hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001743-10 | Sponsor Protocol Number: GO42216 | Start Date*: 2020-09-29 | ||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
| Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATINGTHE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (M... | ||||||||||||||||||
| Medical condition: Advanced liver cancers | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2008-005056-24 | Sponsor Protocol Number: BAY 43-9006 / 12918 | Start Date*: 2009-03-13 | |||||||||||
| Sponsor Name:Bayer HealthCare AG, 51368 Leverkusen, Germany | |||||||||||||
| Full Title: A Phase II randomized, double-blind, placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolisation (TACE) performed with DC Bead and doxorubicin for intermedi... | |||||||||||||
| Medical condition: This study will evaluate the efficacy and safety of TACE (transarterial chemoembolization) performed with DC Bead and doxorubicin plus sorafenib versus TACE performed with DC Bead and doxorubicin ... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-000885-13 | Sponsor Protocol Number: UC-0105/1303 | Start Date*: 2013-07-31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with metastatic or unresectable locally advanced malignancies harboring specific genomic alterations regarding the biological crizotinib targets, and who are no more amenable to curative t... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-005068-13 | Sponsor Protocol Number: I4T-MC-JVDE | Start Date*: 2015-08-07 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma a... | |||||||||||||
| Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) AT (Completed) CZ (Completed) PL (Completed) BE (Completed) FR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-001699-39 | Sponsor Protocol Number: HER117158 | Start Date*: 2015-03-11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Research Development Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with adva... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Subjects with advanced HER3-positive solid tumors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2012-003308-10 | Sponsor Protocol Number: ARQ197-A-U303 | Start Date*: 2012-12-20 | |||||||||||
| Sponsor Name:DAIICHI SANKIO DEVELOPMENT LIMITED | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy | |||||||||||||
| Medical condition: MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) NL (Completed) ES (Completed) FR (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002470-40 | Sponsor Protocol Number: PROSORA | Start Date*: 2017-11-16 |
| Sponsor Name:Erasmus MC Cancer Institute | ||
| Full Title: Observational study of the effects of probenecid on the pharmacokinetics and pharmacodynamics of sorafenib (PROSORA-study) | ||
| Medical condition: patients with unresectable hepatocellular cancer, advanced clear-cell renal cell carcinoma, locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-002013-20 | Sponsor Protocol Number: ALKS4230-001 | Start Date*: 2020-02-14 | |||||||||||||||||||||||||||||||
| Sponsor Name:Alkermes, Inc. | |||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2) | |||||||||||||||||||||||||||||||||
| Medical condition: Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Temporarily Halted) NL (Completed) FR (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2005-005732-27 | Sponsor Protocol Number: UCSC-OM-SU-01 | Start Date*: 2006-12-21 | |||||||||||
| Sponsor Name:Policlinico Universitario Agustino Gemelli | |||||||||||||
| Full Title: EFFICACY AND SAFETY OF THE MULTITARGET INHIBITOR AGENT SU11248 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA | |||||||||||||
| Medical condition: Advanced (localized disease but surgically unresectable or metastatic) histologically/cytologically proven hepatocellular carcinoma (or hepatic lesion and aFP ³ 400 ng/ml). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003172-12 | Sponsor Protocol Number: KY1044-CT01 | Start Date*: 2019-03-07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Kymab Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Advanced/metastatic malignancies, and preferred indications: head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal cancer, ga... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) HU (Completed) PL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-001907-33 | Sponsor Protocol Number: S2472 | Start Date*: 2022-07-21 | |||||||||||
| Sponsor Name:Biocompatibles UK Ltd, a wholly owned indirect subsidiary of Boston Scientific Corporation | |||||||||||||
| Full Title: An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial To Evaluate The Efficacy and Safety Of TheraSphere™ followed by Durvalumab (Imfinzi®) With Tremelimumab, Versus TheraSphere™ Alon... | |||||||||||||
| Medical condition: hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Temporarily Halted) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-002430-36 | Sponsor Protocol Number: AIO-HEP-0418-DEMAND | Start Date*: 2020-03-23 | |||||||||||
| Sponsor Name:Klinikum der Ludwig-Maximilians-Universität München - [...] | |||||||||||||
| Full Title: A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progress... | |||||||||||||
| Medical condition: Unresectable hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-002211-26 | Sponsor Protocol Number: PX115.1.1-201 | Start Date*: 2006-09-10 | |||||||||||
| Sponsor Name:Pharmexa A/S | |||||||||||||
| Full Title: “Heptovax” - Ensayo de fase II, abierto, para evaluar la seguridad y la eficacia de GV1001 para el carcinoma hepatocelular avanzado. (CHC). | |||||||||||||
| Medical condition: Carcinoma hepatocelular avanzado | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-007155-27 | Sponsor Protocol Number: ARQ197-215 | Start Date*: 2009-10-22 | |||||||||||
| Sponsor Name:ArQule, Inc. | |||||||||||||
| Full Title: A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients with Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | |||||||||||||
| Medical condition: Unresectable hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005375-14 | Sponsor Protocol Number: TS-104 | Start Date*: 2013-06-03 | ||||||||||||||||
| Sponsor Name:Biocompatibles UK Ltd | ||||||||||||||||||
| Full Title: A prospective randomized clinical trial on 90Yttrium trans-arterial radio-Embolization (Therasphere) vs. standard of care (sorafenib) for the treatment of advanced Hepatocellular carcinoma (HCC) ... | ||||||||||||||||||
| Medical condition: Advanced Hepatocellular Carcinoma (HCC) with Portal Vein Thrombosis (PVT) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-005086-41 | Sponsor Protocol Number: B1030-101 | Start Date*: 2022-12-06 | ||||||||||||||||||||||||||
| Sponsor Name:SOTIO Biotech Inc | ||||||||||||||||||||||||||||
| Full Title: A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T cells in Subjects With Advanced GPC3-Positive Solid Tumors. | ||||||||||||||||||||||||||||
| Medical condition: Histologically confirmed advanced unresectable or metastatic hepatocellular carcinoma (HCC), squamous cell carcinoma (SCC) of the lung, myxoid/round cell liposarcoma, or Merkel cell carcinoma (MCC)... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2017-003653-42 | Sponsor Protocol Number: CRO-2017-34 | Start Date*: 2018-11-20 | |||||||||||
| Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO | |||||||||||||
| Full Title: Phase II study to assess efficacy and safety of metronomic oral Idarubicin in patients with hepatocarcinoma at intermediate-advanced stage after failure or intolerance to Sorafenib and Regorafenib | |||||||||||||
| Medical condition: Patients with interemdiate-advanced stage hepatocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-000912-34 | Sponsor Protocol Number: PR003-CLN-pro001 | Start Date*: 2008-05-07 | |||||||||||
| Sponsor Name:Protherics Development Medicines Ltd | |||||||||||||
| Full Title: A PHASE 2 STUDY OF THE ANTI-TUMOUR ACTIVITY AND SAFETY OF PROLARIX™ IN HEPATOCELLULAR CARCINOMA (HCC) | |||||||||||||
| Medical condition: Hepatocellular Carcinoma (HCC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002041-36 | Sponsor Protocol Number: POLARIS2009-001 | Start Date*: 2011-11-15 | |||||||||||
| Sponsor Name:Polaris Group | |||||||||||||
| Full Title: A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Fai... | |||||||||||||
| Medical condition: Advanced Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) IT (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
